186 related articles for article (PubMed ID: 19102668)
1. Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis.
Rogers DP; Goldsmith CA
Expert Rev Neurother; 2009 Jan; 9(1):47-54. PubMed ID: 19102668
[TBL] [Abstract][Full Text] [Related]
2. The case for autoimmunity in the etiology of schizophrenia.
Goldsmith CA; Rogers DP
Pharmacotherapy; 2008 Jun; 28(6):730-41. PubMed ID: 18503401
[TBL] [Abstract][Full Text] [Related]
3. [The quest for the pharmacological treatment of schizophrenia: from conventional neuroleptics to atypical antipsychotics and beyond].
Dratcu L
Vertex; 2010; 21(93):385-93. PubMed ID: 21218203
[TBL] [Abstract][Full Text] [Related]
4. [Pathophysiology of schizophrenia and its impact on pharmacotherapy].
Widschwendter CG; Fleischhacker WW
Fortschr Neurol Psychiatr; 2005 Nov; 73 Suppl 1():S32-7. PubMed ID: 16270242
[TBL] [Abstract][Full Text] [Related]
5. Schizophrenia: diverse approaches to a complex disease.
Sawa A; Snyder SH
Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
[TBL] [Abstract][Full Text] [Related]
6. Cytokines in schizophrenia and the effects of antipsychotic drugs.
Drzyzga L; Obuchowicz E; Marcinowska A; Herman ZS
Brain Behav Immun; 2006 Nov; 20(6):532-45. PubMed ID: 16580814
[TBL] [Abstract][Full Text] [Related]
7. The complexity of the dopaminergic synapses and their modulation by antipsychotics.
Leuner K; Müller WE
Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891
[TBL] [Abstract][Full Text] [Related]
8. [Receptor polymorphism and response to treatment in schizophrenia].
Szekeres G; Janka Z
Orv Hetil; 2002 Sep; 143(35):2027-33. PubMed ID: 12387196
[TBL] [Abstract][Full Text] [Related]
9. The development of new drugs for the treatment of schizophrenia.
Cookson J
Br J Hosp Med; 1987 Dec; 38(6):542-8. PubMed ID: 2893648
[TBL] [Abstract][Full Text] [Related]
10. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl SM; Mignon L; Meyer JM
Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotics in the early stage of development.
Biedermann F; Fleischhacker WW
Curr Opin Psychiatry; 2009 May; 22(3):326-30. PubMed ID: 19346948
[TBL] [Abstract][Full Text] [Related]
12. Alterations of dopamine and serotonin transmission in schizophrenia.
Remington G
Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
[TBL] [Abstract][Full Text] [Related]
13. Antipsychotic drug actions on gene modulation and signaling mechanisms.
Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
[TBL] [Abstract][Full Text] [Related]
14. Serotonergic approaches in the development of novel antipsychotics.
Jones CA; McCreary AC
Neuropharmacology; 2008 Nov; 55(6):1056-65. PubMed ID: 18621404
[TBL] [Abstract][Full Text] [Related]
15. [New pharmacological approaches to the treatment of schizophrenia].
Uzbay IT
Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
[TBL] [Abstract][Full Text] [Related]
16. Schizophrenia: moving beyond monoamine antagonists.
Conn PJ; Tamminga C; Schoepp DD; Lindsley C
Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
[TBL] [Abstract][Full Text] [Related]
17. The chakragati mouse: a mouse model for rapid in vivo screening of antipsychotic drug candidates.
Dawe GS; Ratty AK
Biotechnol J; 2007 Nov; 2(11):1344-52. PubMed ID: 17886239
[TBL] [Abstract][Full Text] [Related]
18. Recognition and optimal management of schizophrenia and related psychoses.
Singh B
Intern Med J; 2005 Jul; 35(7):413-8. PubMed ID: 15958112
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenetics of antipsychotics in schizophrenia].
Méary A
Therapie; 2008; 63(3):243-6. PubMed ID: 18718213
[TBL] [Abstract][Full Text] [Related]
20. [Physiopathology of schizophrenia. Some biologic aspects].
Tissot R
Schweiz Arch Neurol Neurochir Psychiatr; 1984; 135(1):29-40. PubMed ID: 6148787
[No Abstract] [Full Text] [Related]
[Next] [New Search]
